EMEA-002559-PIP03-19
Key facts
| Active substance |
Anti-neonatal Fe receptor human monoclonal antibody {M281)
|
| Therapeutic area |
Other
|
| Decision number |
P/0363/2020
|
| PIP number |
EMEA-002559-PIP03-19
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of autoimmune haemolytic aneamia
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Momenta Pharmaceuticals, Inc.
E-mail: byork@momentapharma.com |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|